InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch

Reuters
06-13
InspireMD Secures CE Mark Approval for CGuard® Prime EPS, Paving Way for European Launch

InspireMD Inc., a developer of medical devices for stroke prevention, has announced that it has received CE Mark approval under the European Medical Device Regulation $(MDR.AU)$ for its CGuard® Prime Embolic Prevention System $(EPS)$. This approval is a significant milestone for the company, enabling the commercial launch of CGuard™ Prime EPS across its current CE marked markets in Europe. The CGuard Prime® system, which incorporates user feedback to enhance deliverability and deployment, features a proprietary MicroNet™ mesh designed to reduce embolic events. With this approval, InspireMD is poised to expand its leadership in carotid stenting innovation and plans to launch the platform in the United States later this year, pending FDA approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-014986), on June 13, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10